Campbell R K
Drug Intell Clin Pharm. 1981 Apr;15(4):257-62. doi: 10.1177/106002808101500402.
Narcolepsy may affect as many as 250,000 Americans. It involves a neurologic defect in the regulation of sleep and wakefulness. The chief symptoms are sleepiness, inappropriate sleep episodes, and cataplexy. Narcoleptic patients also frequently complain of hypnagogic hallucinations, sleep paralysis, and automatic behavior, as well as disturbed nocturnal sleep. Narcolepsy usually develops in adolescence and is a life-long illness. Satisfactory treatment is not available at the present time. The current treatments of choice include general measures (such as patient and family counseling and frequent napping) and drug treatments, including methylphenidate for sleepiness and sleep episodes and imipramine for cataplexy. Medication dosages mut be adjusted for individual patients. Pharmacists have a special responsibility to monitor narcoleptic patients by becoming familiar with the disease and its symptoms and by encouraging patients to follow their drug regimens and to take drug holidays under the supervision of the physician when the drug dose becomes excessive.
发作性睡病可能影响多达25万美国人。它涉及睡眠和清醒调节方面的神经缺陷。主要症状包括嗜睡、不适当的睡眠发作和猝倒。发作性睡病患者还经常抱怨入睡前幻觉、睡眠麻痹和自动行为,以及夜间睡眠障碍。发作性睡病通常在青春期发病,是一种终身疾病。目前尚无令人满意的治疗方法。目前的首选治疗方法包括一般措施(如对患者及其家属进行咨询和频繁小睡)和药物治疗,包括使用哌甲酯治疗嗜睡和睡眠发作,使用丙咪嗪治疗猝倒。药物剂量必须根据个体患者进行调整。药剂师有特殊责任通过熟悉该疾病及其症状来监测发作性睡病患者,并鼓励患者遵循药物治疗方案,在药物剂量过大时在医生监督下进行药物假期。